HRP20220096T1 - Inhibitori lizin specifične demetilaze-1 - Google Patents

Inhibitori lizin specifične demetilaze-1 Download PDF

Info

Publication number
HRP20220096T1
HRP20220096T1 HRP20220096TT HRP20220096T HRP20220096T1 HR P20220096 T1 HRP20220096 T1 HR P20220096T1 HR P20220096T T HRP20220096T T HR P20220096TT HR P20220096 T HRP20220096 T HR P20220096T HR P20220096 T1 HRP20220096 T1 HR P20220096T1
Authority
HR
Croatia
Prior art keywords
methyl
fluoro
oxo
dihydro
benzonitrile
Prior art date
Application number
HRP20220096TT
Other languages
English (en)
Croatian (hr)
Inventor
Young K. Chen
Toufike Kanouni
Stephen W. Kaldor
Jeffrey Alan Stafford
James Marvin Veal
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of HRP20220096T1 publication Critical patent/HRP20220096T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
HRP20220096TT 2014-05-01 2015-04-30 Inhibitori lizin specifične demetilaze-1 HRP20220096T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987354P 2014-05-01 2014-05-01
PCT/US2015/028635 WO2015168466A1 (en) 2014-05-01 2015-04-30 Inhibitors of lysine specific demethylase-1
EP15785884.6A EP3137169B1 (en) 2014-05-01 2015-04-30 Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
HRP20220096T1 true HRP20220096T1 (hr) 2022-04-15

Family

ID=54354743

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220096TT HRP20220096T1 (hr) 2014-05-01 2015-04-30 Inhibitori lizin specifične demetilaze-1

Country Status (32)

Country Link
US (9) US9255097B2 (enExample)
EP (1) EP3137169B1 (enExample)
JP (1) JP6493890B2 (enExample)
KR (1) KR102400920B1 (enExample)
CN (1) CN106659914B (enExample)
AR (1) AR100251A1 (enExample)
AU (1) AU2015253040B2 (enExample)
BR (1) BR112016025248B1 (enExample)
CA (1) CA2947283C (enExample)
CL (1) CL2016002736A1 (enExample)
CY (1) CY1124959T1 (enExample)
DK (1) DK3137169T3 (enExample)
EA (1) EA036672B8 (enExample)
ES (1) ES2903423T3 (enExample)
HR (1) HRP20220096T1 (enExample)
HU (1) HUE057895T2 (enExample)
IL (1) IL248505B (enExample)
LT (1) LT3137169T (enExample)
MX (1) MX373373B (enExample)
NI (1) NI201600165A (enExample)
PE (1) PE20161438A1 (enExample)
PH (1) PH12016502179A1 (enExample)
PL (1) PL3137169T3 (enExample)
PT (1) PT3137169T (enExample)
RS (1) RS62874B1 (enExample)
SA (2) SA516380201B1 (enExample)
SG (1) SG11201609033TA (enExample)
SI (1) SI3137169T1 (enExample)
SM (1) SMT202200066T1 (enExample)
TW (1) TWI676620B (enExample)
WO (1) WO2015168466A1 (enExample)
ZA (1) ZA201607613B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699354T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-(triazin-3-il/piridazin-3-il)-piper(-azin)idina y composiciones de las mismas para inhibir la actividad de SHP2
PE20161438A1 (es) * 2014-05-01 2017-01-18 Celgene Quanticel Res Inc Inhibidores de desmetilasa 1 especifica a lisina
PL3160956T3 (pl) * 2014-06-27 2020-11-30 Celgene Quanticel Research, Inc. Inhibitory demetylazy-1 specyficznej dla lizyny
SMT202300205T1 (it) * 2014-07-03 2023-09-06 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
ES2824576T3 (es) * 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
ES2805232T3 (es) 2015-06-19 2021-02-11 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017079476A1 (en) 2015-11-05 2017-05-11 Mirati Therapeutics, Inc. Lsd1 inhibitors
ES2846951T3 (es) * 2015-11-05 2021-07-30 Celgene Quanticel Res Inc Composiciones que comprenden un inhibidor de desmetilasa-1 específica para lisina, que tiene un anillo de pirimidina, y su uso en el tratamiento del cáncer
JP6510068B2 (ja) 2015-11-27 2019-05-08 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
US9809541B2 (en) 2015-12-29 2017-11-07 Mirati Therapeutics, Inc. LSD1 inhibitors
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US11034991B2 (en) 2016-03-16 2021-06-15 Oryzon Genomics S.A. Methods to determine KDM1A target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN109415360B (zh) 2016-06-14 2021-11-02 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
CN109803660A (zh) * 2016-08-10 2019-05-24 细胞基因公司 复发性和/或难治性实体瘤和非霍奇金淋巴瘤的治疗
EP3523290A4 (en) * 2016-09-30 2020-07-29 Novartis AG IMPROVED EFFICIENCY IMMUNE EFFICIENT CELL THERAPIES
US20190256929A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
JP7442439B2 (ja) 2017-03-30 2024-03-04 アルベルト－ルートヴィヒ－ユニバーシティー フライブルク Ｋｄｍ４阻害剤
RU2765152C2 (ru) * 2017-05-26 2022-01-26 Тайхо Фармасьютикал Ко., Лтд. Новое соединение бифенила или его соль
TWI770925B (zh) * 2017-05-26 2022-07-11 日商大鵬藥品工業股份有限公司 使用有新穎聯苯化合物之抗腫瘤效果增強劑
JP6915056B2 (ja) 2017-05-31 2021-08-04 大鵬薬品工業株式会社 Ｉｎｓｍ１の発現に基づくｌｓｄ１阻害剤の治療効果の予測方法
CA3071804A1 (en) 2017-08-03 2019-02-07 Oryzon Genomics, S.A. Use of a kdm1a inhibitor in the treatment of behavior alterations
CN112368272B (zh) * 2018-03-21 2023-04-21 苏州浦合医药科技有限公司 Shp2抑制剂及其用途
CN109668987A (zh) * 2019-02-27 2019-04-23 浙江华贝药业有限责任公司 一种3-氨基哌啶二盐酸盐对映异构体测定分析方法
HRP20260110T1 (hr) 2019-03-20 2026-03-13 Oryzon Genomics, S.A. Vafidemstat za liječenje neagresivnih simptoma graničnog poremećaja osobnosti
CN113631164A (zh) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
CA3143030A1 (en) 2019-06-13 2020-12-17 Celgene Corporation Methods of treating cancer by targeting cold tumors
JP2022537384A (ja) * 2019-06-20 2022-08-25 セルジーン コーポレーション ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
WO2021063821A1 (en) * 2019-10-01 2021-04-08 Bayer Aktiengesellschaft Pyrimidinedione derivatives
EP4058018A4 (en) 2019-11-13 2023-06-21 Taiho Pharmaceutical Co., Ltd. METHODS OF TREATING LSD1-ASSOCIATED DISEASES AND DISORDERS WITH LSD1 INHIBITORS
BR112022017637A2 (pt) * 2020-03-06 2022-11-08 Celgene Quanticel Res Inc Métodos de tratamento do câncer de pulmão de células pequenas e/ou câncer de pulmão de células não pequenas
EP4161507A1 (en) 2020-06-05 2023-04-12 Celgene Quanticel Research, Inc. Methods of treating prostate cancer
CN117015540A (zh) * 2021-03-11 2023-11-07 南京明德新药研发有限公司 噻吩类化合物及其应用
CN117062813A (zh) * 2021-03-24 2023-11-14 四川汇宇制药股份有限公司 一种多环化合物及其应用
MX2023011779A (es) 2021-04-08 2023-11-22 Oryzon Genomics Sa Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides.
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
US20250275969A1 (en) 2022-05-09 2025-09-04 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
CN120379982A (zh) 2022-12-02 2025-07-25 纽摩拉治疗公司 治疗神经障碍的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
CN1312807A (zh) * 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
HUP0402352A2 (hu) * 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
ES2412273T3 (es) * 2002-11-21 2013-07-10 Novartis Ag Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US8466163B2 (en) * 2006-12-11 2013-06-18 Bionomics Limited Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
KR20110041536A (ko) * 2008-07-29 2011-04-21 베링거 인겔하임 인터내셔날 게엠베하 5-알키닐-피리미딘
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
EP2568812B1 (en) * 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
JP5813855B2 (ja) 2011-03-25 2015-11-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ Ｌｓｄ１阻害剤としてのシクロプロピルアミン
JP6195828B2 (ja) 2012-05-24 2017-09-13 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
MX2015012158A (es) 2013-03-11 2015-12-01 Abbvie Inc Inhibidores de bomodominio tetraciclicos fusionados.
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
AU2014337064B2 (en) 2013-10-18 2019-03-14 Celgene Quanticel Research, Inc. Bromodomain inhibitors
CA3161836A1 (en) * 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
PE20161438A1 (es) * 2014-05-01 2017-01-18 Celgene Quanticel Res Inc Inhibidores de desmetilasa 1 especifica a lisina
US20160022684A1 (en) 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
CA2966452A1 (en) 2014-12-17 2016-06-23 Samuel David Brown Substituted bicyclic compounds as bromodomain inhibitors
ES2846951T3 (es) * 2015-11-05 2021-07-30 Celgene Quanticel Res Inc Composiciones que comprenden un inhibidor de desmetilasa-1 específica para lisina, que tiene un anillo de pirimidina, y su uso en el tratamiento del cáncer

Also Published As

Publication number Publication date
WO2015168466A8 (en) 2016-11-24
ES2903423T3 (es) 2022-04-01
IL248505A0 (en) 2016-12-29
SMT202200066T1 (it) 2022-03-21
CA2947283A1 (en) 2015-11-05
EA036672B8 (ru) 2021-01-13
US20170349556A1 (en) 2017-12-07
JP2017514830A (ja) 2017-06-08
NI201600165A (es) 2017-03-13
US9255097B2 (en) 2016-02-09
PH12016502179A1 (en) 2017-02-13
CA2947283C (en) 2023-01-24
CN106659914A (zh) 2017-05-10
CY1124959T1 (el) 2023-01-05
EA036672B1 (ru) 2020-12-07
MX2016014253A (es) 2017-02-08
SA516380201B1 (ar) 2019-11-20
CL2016002736A1 (es) 2017-06-23
TWI676620B (zh) 2019-11-11
US9776974B2 (en) 2017-10-03
EP3137169A4 (en) 2018-01-10
US20220153706A1 (en) 2022-05-19
WO2015168466A1 (en) 2015-11-05
AU2015253040A1 (en) 2016-11-24
KR102400920B1 (ko) 2022-05-20
US20180325900A1 (en) 2018-11-15
US20170114024A1 (en) 2017-04-27
EP3137169A1 (en) 2017-03-08
US20160152595A1 (en) 2016-06-02
PL3137169T3 (pl) 2022-02-28
US10207999B2 (en) 2019-02-19
JP6493890B2 (ja) 2019-04-03
NZ725914A (en) 2023-09-29
AR100251A1 (es) 2016-09-21
BR112016025248A2 (pt) 2018-06-19
US9573930B2 (en) 2017-02-21
US20150315187A1 (en) 2015-11-05
SG11201609033TA (en) 2016-11-29
KR20160144506A (ko) 2016-12-16
SA519410025B1 (ar) 2022-06-01
MX373373B (es) 2020-05-12
US10654810B2 (en) 2020-05-19
US10023543B2 (en) 2018-07-17
AU2015253040A8 (en) 2017-06-15
EP3137169B1 (en) 2021-11-10
US20170349555A1 (en) 2017-12-07
BR112016025248B1 (pt) 2022-12-13
US20160130247A1 (en) 2016-05-12
ZA201607613B (en) 2017-11-29
LT3137169T (lt) 2022-04-11
PT3137169T (pt) 2022-01-25
EA201692079A1 (ru) 2017-04-28
AU2015253040B2 (en) 2020-04-09
US9771329B2 (en) 2017-09-26
HUE057895T2 (hu) 2022-06-28
IL248505B (en) 2021-01-31
DK3137169T3 (da) 2022-02-14
SI3137169T1 (sl) 2022-04-29
US11084793B2 (en) 2021-08-10
CN106659914B (zh) 2020-06-19
PE20161438A1 (es) 2017-01-18
US20200231549A1 (en) 2020-07-23
RS62874B1 (sr) 2022-02-28
TW201623254A (zh) 2016-07-01
US11987560B2 (en) 2024-05-21

Similar Documents

Publication Publication Date Title
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
HRP20180382T1 (hr) Inhibitori protein kinaze
HRP20210482T1 (hr) Inhibitori serinske/treoninske kinaze
JP2014531465A5 (enExample)
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2016519156A5 (enExample)
RU2015154987A (ru) Гетероциклические производные
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2016519096A5 (enExample)
JP2018516254A5 (enExample)
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
HRP20230595T1 (hr) Inhibitori lizina specifične demetilaze-1
JP2016530299A5 (enExample)
JP2015500332A5 (enExample)
JP2018118992A5 (enExample)
JP2013527173A5 (enExample)
JP2017500364A5 (enExample)
HRP20200098T1 (hr) Spirociklični spojevi kao inhibitori triptofan hidroksilaze
JP2015508828A5 (enExample)
RU2018112237A (ru) Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2014528446A5 (enExample)
RU2015137615A (ru) Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
JP2019537571A5 (enExample)
HRP20201469T1 (hr) Derivati tetrahidroizokinolina